Compare SNTG & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNTG | ARTL |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.3M |
| IPO Year | 2020 | N/A |
| Metric | SNTG | ARTL |
|---|---|---|
| Price | $1.97 | $1.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 178.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.94 |
| 52 Week High | $12.70 | $28.60 |
| Indicator | SNTG | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 25.82 |
| Support Level | $1.83 | $1.08 |
| Resistance Level | $2.10 | $1.96 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 29.31 | 3.47 |
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.